KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia

被引：0
|
作者：
Hauser, Robert [6 ]
Factor, Stewart [2 ]
Marder, Stephen [4 ]
Knesevich, Mary Ann [5 ]
Ramirez, Paul Michael [1 ]
Jimenez, Roland [3 ]
Burke, Joshua [3 ]
Liang, Grace [3 ]
O'Brien, Christopher [3 ]
机构：
[1] CNS Ratings LLC, Kingston, NY USA
[2] Emory Univ, Sch Med, Atlanta, GA USA
[3] Neurocrine Biosci Inc, San Diego, CA USA
[4] Univ Calif Los Angeles, Semel Inst Neurosci, Los Angeles, CA USA
[5] Univ Hills Clin Res, Irving, TX USA
[6] Univ S Florida, Parkinsons Dis & Movement Disorders Ctr, Tampa, FL USA
来源：
NEUROLOGY | 2016年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PL02.003
引用
收藏
页数：2
相关论文
共 50 条
  • [1] KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia
    Factor, S. A.
    Hauser, R. A.
    Siegert, S.
    Liang, G. S.
    O'Brien, C. F.
    [J]. MOVEMENT DISORDERS, 2016, 31 : S692 - S692
  • [2] KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia
    Hauser, Robert A.
    Factor, Stewart A.
    Marder, Stephen R.
    Knesevich, Mary Ann
    Ramirez, Paul M.
    Jimenez, Roland
    Burke, Joshua
    Liang, Grace S.
    O'Brien, Christopher F.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2017, 174 (05): : 476 - 484
  • [3] Valbenazine (NBI-98854) Treatment for Tardive Dyskinesia in Subjects 65 Years or Older: Pooled Results from 3 Randomized, Double-Blind, Placebo-Controlled Trials
    Molho, E. S.
    Singer, C.
    Burke, J.
    Siegert, S.
    Board, T.
    Sheth, B.
    Liang, G. S.
    [J]. MOVEMENT DISORDERS, 2017, 32 (09) : E16 - E16
  • [4] NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study
    O'Brien, Christopher F.
    Jimenez, Roland
    Hauser, Robert A.
    Factor, Stewart A.
    Burke, Joshua
    Mandri, Daniel
    Castro-Gayol, Julio C.
    [J]. MOVEMENT DISORDERS, 2015, 30 (12) : 1681 - 1687
  • [5] A Phase 2 Study of Valbenazine (NBI-98854) for Treatment of Tardive Dyskinesia: KINECT 2
    Factor, Stewart
    Hauser, Robert
    Mandri, Daniel
    Castro-Gayol, Julio
    Jimenez, Roland
    Siegert, Scott
    O'Brien, Christopher
    [J]. NEUROLOGY, 2016, 86
  • [6] VALBENAZINE (NBI-98854) FOR THE TREATMENT OF TARDIVE DYSKINESIA: ANALYSIS BY UNDERLYING PSYCHIATRIC DIAGNOSIS IN PHASE III KINECT 3 STUDY
    Josiassen, Richard
    Kane, John
    Burke, Joshua
    Jimenez, Roland
    Siegert, Scott
    Liang, Grace
    [J]. SCHIZOPHRENIA BULLETIN, 2017, 43 : S217 - S217
  • [7] Open-Label Extension of KINECT: A Phase 2 Study of Valbenazine (NBI-98854) for Tardive Dyskinesia
    Bari, Mohammed
    Shiwach, Raj
    Jimenez, Roland
    Siegert, Scott
    O'Brien, Christopher
    [J]. NEUROLOGY, 2016, 86
  • [8] Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension)
    Factor, Stewart
    Comella, Cynthia
    Correll, Christoph
    Liang, Grace
    Burke, Joshua
    O'Brien, Christopher
    [J]. NEUROLOGY, 2017, 88
  • [9] Efficacy of Valbenazine (NBI-98854) in Subjects With Tardive Dyskinesia: Results of a Long-Term Extension Study (KINECT 3 Extension)
    Grigoriadis, Dimitri
    Comella, Cynthia
    Remington, Gary
    Jimenez, Roland
    Burke, Joshua
    Christopher, O'Brien
    [J]. NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S213 - S214
  • [10] EFFICACY AND SAFETY OF VALBENAZINE (NBI-98854) IN SUBJECTS WITH TARDIVE DYSKINESIA: RESULTS OF A LONG-TERM STUDY (KINECT 3 EXTENSION)
    Siegert, S.
    Factor, S.
    Liang, G.
    Burke, J.
    [J]. PARKINSONISM & RELATED DISORDERS, 2018, 46 : E35 - E35
12345